Stroke Prevention in Nigeria 2 Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

June 30, 2030

Conditions
Sickle Cell DiseaseStroke
Interventions
DRUG

Hydroxyurea

The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.

Trial Locations (2)

Unknown

RECRUITING

Aminu Kano Teaching Hospital, Kano

RECRUITING

Murtala Muhammad Specialist Hospital, Kano

All Listed Sponsors
collaborator

Aminu Kano Teaching Hospital

OTHER

collaborator

Murtala Muhammed Specialist Hospital

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Vanderbilt University Medical Center

OTHER